文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

通气相关医院获得性肺炎与呼吸机相关性肺炎的死亡率决定因素

Determinants of Mortality for Ventilated Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.
PubMed 文献 · Crit Care Explor · 2023-02-24
一句话结论单中心回顾性队列显示,调整混杂因素后通气相关医院获得性肺炎(vHAP)是30天全因死亡的独立预测因素(AOR 1.77)。

该单中心回顾性队列研究纳入2016至2019年Barnes-Jewish医院1120例次成人肺炎出院诊断患者(vHAP 410例,VAP 710例),比较两类机械通气相关院内肺炎的30天全因死亡率。vHAP组30天全因死亡率高于VAP组(37.1% vs 28.5%;p=0.003)。多因素logistic回归显示,vHAP(AOR 1.77;95% CI 1.51-2.07)、使用血管升压药(AOR 2.34;95% CI 1.94-2.82)、Charlson合并症指数每增加1分(AOR 1.21;95% CI 1.18-1.24)、抗生素总治疗天数每增加1天(AOR 1.13;95% CI 1.11-1.14)及APACHE II评分每增加1分(AOR 1.04;95% CI 1.03-1.06)为30天全因死亡的独立预测因素。作者认为,未来纳入vHAP患者的临床试验需在设计与数据解读中考虑这一结局差异。

要点

  • vHAP组30天全因死亡率高于VAP组(37.1% vs 28.5%;p=0.003)。
  • 调整混杂因素后,vHAP仍是30天全因死亡的独立预测因素(AOR 1.77;95% CI 1.51-2.07)。
  • 使用血管升压药与30天全因死亡独立相关(AOR 2.34;95% CI 1.94-2.82)。
  • Charlson合并症指数每增加1分,30天全因死亡风险增加(AOR 1.21;95% CI 1.18-1.24)。
  • 抗生素总治疗天数每增加1天(AOR 1.13;95% CI 1.11-1.14)及APACHE II评分每增加1分(AOR 1.04;95% CI 1.03-1.06)亦为独立预测因素。

适用人群与场景

  • 2016至2019年在Barnes-Jewish医院(圣路易斯)出院诊断为肺炎的成人患者,诊断为vHAP和VAP者纳入。
  • 本研究为单中心回顾性队列,数据来自电子健康记录。

研究设计与关键结果

  • 研究类型:单中心回顾性队列研究;样本量1120例次(vHAP 410例,VAP 710例);人群:成人肺炎出院诊断患者。
  • 主要终点:30天全因死亡率vHAP组37.1% vs VAP组28.5%(p=0.003)。
  • 多因素logistic回归:vHAP(AOR 1.77;95% CI 1.51-2.07)、使用血管升压药(AOR 2.34;95% CI 1.94-2.82)、Charlson合并症指数每增加1分(AOR 1.21;95% CI 1.18-1.24)、抗生素总治疗天数每增加1天(AOR 1.13;95% CI 1.11-1.14)、APACHE II评分每增加1分(AOR 1.04;95% CI 1.03-1.06)为30天全因死亡的独立预测因素。
  • vHAP和VAP最常见的细菌病原体为金黄色葡萄球菌、肠杆菌科菌种和铜绿假单胞菌。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,纳入vHAP患者的临床试验需在试验设计与数据解读中考虑vHAP与VAP之间30天全因死亡率的差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Hospital-acquired pneumonia (HAP) is the most common hospital-acquired infection, accounting for 22% of all nosocomial infections. The available studies to date have not attempted to assess whether confounding factors may account for the observed difference in mortality for the two forms of nosocomial pneumonia associated with mechanical ventilation, namely ventilated HAP (vHAP) and ventilator-associated pneumonia (VAP).

OBJECTIVES: To determine if vHAP is an independent predictor of mortality among patients with nosocomial pneumonia.

DESIGN SETTING AND PARTICIPANTS: Single-center retrospective cohort study conducted at Barnes-Jewish Hospital, St. Louis, MO, between 2016 and 2019. Adult patients with a pneumonia discharge diagnosis were screened and patients diagnosed with vHAP and VAP were included. All patient data was extracted from the electronic health record.

MAIN OUTCOMES AND MEASURES: The primary outcome was 30-day all-cause mortality (ACM).

RESULTS: One thousand one-hundred twenty unique patient admissions were included (410 vHAP, 710 VAP). Thirty-day ACM was greater for patients with vHAP compared with VAP (37.1% vs 28.5%; p = 0.003). Logistic regression analysis identified vHAP (adjusted odds ratio [AOR], 1.77; 95% CI, 1.51-2.07), vasopressor use (AOR, 2.34; 95% CI, 1.94-2.82), Charlson Comorbidity Index (1-point increments) (AOR, 1.21; 95% CI, 1.18-1.24), total antibiotic treatment days (1-d increments) (AOR, 1.13; 95% CI, 1.11-1.14), and Acute Physiology and Chronic Health Evaluation II score (1-point increments) (AOR, 1.04; 95% CI, 1.03-1.06) as independent predictors of 30-day ACM. The most common bacterial pathogens identified as causes of vHAP and VAP were Staphylococcus aureus, Enterobacterales species, and Pseudomonas aeruginosa.

CONCLUSIONS AND RELEVANCE: In this single-center cohort study with low rates of initial inappropriate antibiotic therapy, vHAP had greater 30-day ACM compared with VAP after adjusting for potential confounding variables including disease severity and comorbidities. This finding suggests that clinical trials enrolling patients with vHAP need to account for this outcome difference in their trial design and data interpretation.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Motowski H, Ilges D, Hampton N, et al. Determinants of Mortality for Ventilated Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. Crit Care Explor. 2023. PMID: 36861046. doi:10.1097/CCE.0000000000000867

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。